Differential expression of the suppressor PML and Ki-67 identifies three subtypes of human nasopharyngeal carcinoma

European Journal of Cancer

Volumn 38, Issue 12, 2002, Pages 1600-1606

  Chan, J Y H ^a,c   Meng, C L ^b   To, K F ^b   Leung, S F ^b   Chan, A T C ^b   Lee, K K H ^b   Johnson, P J ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bax; CBP; Ki 67; Nasopharyngeal carcinoma; PML; Suppressor

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; KI 67 ANTIGEN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN; PROTEIN BAX; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER TISSUE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

BCL-2-ASSOCIATED X PROTEIN; CREB-BINDING PROTEIN; FEMALE; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0036342357     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00080-1     Document Type: Article

References (36)

1. Nasopharyngeal carcinoma
2. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: Viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma
3. Nasopharyngeal carcinoma: The Epstein-Barr virus association
4. Epidemiology and aetiology
5. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications
6. The PML nuclear bodies: Actors or extras?
7. Acute promyelocytic leukemia: From morphology to molecular lesions
8. Life, death and nuclear spots
9. Structure and function in the nucleus
10. Nuclear structure-gene expression interrelationships: Implications for aberrant gene expression in cancer
11. The promyelocytic leukemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter
12. The PML gene encodes a phosphoprotein associated with the nuclear matrix
13. Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein
14. Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling
15. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body
16. PML induces a novel caspase-independent death process
17. The interferon (IFN)-stimulated gene Sp100 promoter contains an IFN-gamma activation site and an imperfect IFN-stimulated response element, which mediate type I IFN inducibility
18. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukemia
19. Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I Tax oncoprotein
20. Nuclear domain 10 (ND10) associated proteins are also present in nuclear bodies and redistribute to hundreds of nuclear sites after stress
21. Role of SUMO-1 modified PML in nuclear body formation
22. Promyelocytic leukemia (PML) nuclear bodies are protein structure that donot accumulate RNA
23. A role for PML and the nuclear body in genomic stability
24. The transcriptional role of PML and the nuclear body
25. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras
26. The promyelocytic (PML) nuclear compartment and transcription control
27. Sequestration and inhibition of Daxx-mediated transcriptional repression by PML
28. The PML growth-suppressor has an altered expression in human oncogenesis
29. PML nuclear bodies are general targets for inflammation and cell proliferation
30. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues
31. Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal protein of the PML gene product: Immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells and epithelia
32. Cell-cycle regulation of DNA damage-induced expression of the suppressor gene PML
33. Altered expression of the growth and transformation-suppressor PML in human hepatocellular carcinomas and in hepatitis tissues
34. Lack of expression for the suppressor PML in human small cell lung carcinoma
35. Regulation of matrix attachment region-dependent, lymphocyte-restricted transcription through differential localization within promyelocytic leukemia nuclear bodies
36. Expression of p-2, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment